Volume 7, Number 2—April 2001
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections
State of the Art
Economic Impact of Antimicrobial Resistance
|Death||Costs associated with treatment failure (R) - Costs associated with treatment failure (S)||Physician, patient, HCB|
|Illness||Costs associated with pain, suffering, inconvenience (R) - Costs associated with pain, suffering, inconvenience (S)||Physician, patient|
|Care cost||Charges for care (R) - Charges for care (S)||Patient|
|Care time||Time devoted to care (R) - Time devoted to care (S)||Physician, HCB|
|Length of process (R) - Length of process (S)b||Patient, society|
|Diagnosis costs||Costs for diagnosis (R) - Costs for diagnosis (S)||HCB|
|Treatment costs||Costs for drugs (additional drugs and treatments, more expensive drugs)(R) - Costs for drugs(S)||HCB|
|Diminished marketability||Market for drug use (R) - Market for drug use (S)||Drug industry|
|New markets||Market for new drug (S) - New market for new drug (R) (replace current market leader; replace inexpensive drug with more expensive drug; provide new product)||Drug industry|
|Impact on non-treated||Increased resistance (R) - Increased resistance (S)||Society|
aR = extent in patients infected with resistant organism; S = extent in patients infected with susceptible organism; HCB = health-care business.
bCosts associated with lack of routine functions during infection, including loss of work, quality of life for patient (includes both inpatient and outpatient components); for society, reduction of useful function in workforce.
Correction: On July 2, 2001 the following correction was made to this article in the second sentence of paragraph 1. The word "billion" replaced "million" in the phrase "...U.S.$4 to $5 million."